In Mice, Cancer Drug Shows Effect on Alzheimer's
THURSDAY, Feb. 9 (HealthDay News) -- The cancer drug bexarotene
quickly eliminates Alzheimer's disease-associated amyloid beta from
the brain and reverses memory problems in mice, a new study
The results suggest that bexarotene could possibly help the
approximately 5.4 million Americans with Alzheimer's disease,
according to the neuroscientists at Case Western Reserve University
School of Medicine.
However, while studies involving animals can be useful, they
often fail to produce similar results in humans.
Bexarotene is approved in the United States to treat skin
problems caused by cutaneous T-cell lymphoma.
The body's inability to clear amyloid beta from the brain is a
major factor in the development of Alzheimer's disease, according
to a university news release. Previous research showed that the
main cholesterol carrier in the brain, apolipoprotein E (ApeE),
plays an important role in clearing amyloid beta proteins.
In this study, the researchers found that bexarotene increased
ApoE expression, and the elevated levels of ApoE boosted clearance
of amyloid beta from the brain. Bexarotene stimulates retinoid X
receptors (RXR), which are proteins that control the production of
Within six hours of receiving bexarotene, soluble amyloid levels
in the mice fell by 25 percent and the effect lasted for three
days. This decrease was associated with rapid improvement in a wide
number of behaviors in mice with Alzheimer's, according to the
In addition, bexarotene treatment also rapidly stimulated the
removal of amyloid plaques from the brain, the researchers said.
The plaques are accumulations of amyloid that form in the brain and
are a hallmark of Alzheimer's disease.
"This is a particularly exciting and rewarding study because of the new science we have discovered and the potential promise of a therapy for Alzheimer's disease," study senior author Gary Landreth, a professor of neurosciences, said in a university news release.
"We need to be clear; the drug works quite well in mouse models of the disease. Our next objective is to ascertain if it acts similarly in humans. We are at an early stage in translating this basic science discovery into a treatment," he added.
The study appeared Feb. 9 in the journal
The U.S. National Institute on Aging has more about
Copyright © 2012
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.